Alcohol Biomarkers In Post Liver Transplant Patients
肝移植后患者的酒精生物标志物
基本信息
- 批准号:8133325
- 负责人:
- 金额:$ 17.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-20 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:Alcohol abuseAlcohol consumptionAlcoholic Liver DiseasesAlcoholsAreaAttention Deficit DisorderAwardBiological AssayBiological MarkersBlood alcohol level measurementChicagoChildClinical ResearchClinical and Translational Science AwardsCommitControl GroupsCounselingDataDependenceDetectionDiagnosisDoctor of PhilosophyEarly DiagnosisEducationEuropeFacultyFamilyFamily PracticeFamily memberFetal Alcohol Spectrum DisorderFrequenciesFrightFundingGoalsGrantHigh Pressure Liquid ChromatographyHospitalizationInfectionInjuryInjury to LiverInstitute of Medicine (U.S.)InterviewLiverLiver FailureLiver diseasesMeasuresMedicalMedical RecordsMedicineMentored Patient-Oriented Research Career Development AwardMentorsMethylphenidateMinnesotaMonitorOperative Surgical ProceduresOrgan ProcurementsOrgan TransplantationPaperPatient RecruitmentsPatient Self-ReportPatientsPediatricsPhysiciansPostdoctoral FellowPublishingRecording of previous eventsRecruitment ActivityRelapseReportingResearchResearch ActivityResearch PersonnelResearch SupportRiskRisk FactorsSECTM1 geneSamplingScientistShameSouth CarolinaStudentsSubstance abuse problemTestingTimeTraining ActivityTranslational ResearchTransplant RecipientsTransplantationTraumaUnited StatesUnited States National Academy of SciencesUniversitiesValidity and ReliabilityWagesWhole BloodWisconsinWorkWritingalcohol researchbinge drinkingcarbohydrate-deficient transferrincareercostdesigndrinkingdrug cravingefficacy testingexperienceliver transplantationmedical specialtiesperformance testsphosphatidylethanolpreventprofessorprogramsprospectivepublic health relevanceresearch studysuccessworking group
项目摘要
DESCRIPTION (provided by applicant): The goal of this mid-career K24 application is to support the mentoring and research activities of Dr. Michael Fleming. He is committed to continuing an active research program in clinical and translational research. This grant is a competitive renewal that was initially funded in September 2005 and will end in September 2010. He is asking for an additional 5 years of funding. Dr. Fleming successfully completed the two research studies proposed in the initial application, participated in training activities and mentored PhD students, post doctoral fellows and faculty. During the period of the award he was elected to the National Academy of Sciences Institute of Medicine for his alcohol research and mentoring. He is also a national leader among the CTSA (Clinical Translational Science Award) programs and is the chair elect of the national CTSA Education Key Function Committee and Mentor Working Group. Work completed with current K24 grant: The first study evaluated two alcohol biomarkers, Blood Alcohol Levels and Carbohydrate-Deficient Transferrin (CDT), in a sample 214 patients admitted for trauma. The second study tested the efficacy of methylphenidate in a sample 13 children with a diagnosis of Attention Deficit Disorder and Fetal Alcohol Spectrum Disorder. Since 2005 his research group and trainees have published 42 research papers in the substance abuse area. Co-authors of these papers include five students, nine physician post doctoral research fellows, 11 University of Wisconsin-Madison physician faculty and scientists from 12 non-UW research groups. Over the last four years six of his trainees have been awarded K23/K08/K12/K01/R21/R03 grants, one MD PhD student was awarded an F30 and another PhD student an F31 grant. Without the salary and research support provided by the K24 grant much of this work and the success of his trainees would not have been possible. Proposed work for the K24 renewal: The K24 renewal will provide protected time for Dr. Fleming to mentor seven assistant professors in the departments of medicine, pediatrics and family medicine and facilitate his ability to write papers with trainees from three recently completed R01's. He will also initiate a prospective alcohol biomarker study that will test the predictive validity and reliability of Phosphatidylethanol (PEth) and CDT in a sample of 250 post liver transplant patients. Subjects will be recruited from four transplant centers. The biomarkers will be compared to patient self-report, family member interview and transplant staff concerns as well as medical records data. PEth and CDT will be measured at six-month intervals for one year. Significance: The K24 is critical for Dr. Fleming's continued ability to mentor new investigators in alcohol research and for his research on alcohol biomarkers.
PUBLIC HEALTH RELEVANCE: The goal of the study is to find out if a lab test can tell which patients are drinking alcohol after having a liver transplant. A positive study would help physicians identify and treat patients before they damage their new liver.
描述(由申请人提供):此中期K24申请的目的是支持Michael Fleming博士的指导和研究活动。他致力于继续进行临床和转化研究的积极研究计划。该赠款是一种竞争性续约,最初于2005年9月资助,并将于2010年9月结束。他要求额外提供5年的资金。弗莱明博士成功地完成了最初申请中提出的两项研究,参加了培训活动,并指导了博士生,博士后研究员和教职员工。在该奖项期间,他因其酒精研究和指导而当选为美国国家科学院医学院。他还是CTSA(临床翻译科学奖)计划的国家领导者,并且是国家CTSA教育关键职能委员会和导师工作组的主席。用当前的K24赠款完成的工作:第一项研究评估了两种酒精饮酒水平和缺乏碳水化合物的转铁蛋白(CDT)的214例患者。第二项研究测试了哌醋甲酯在样本13名儿童中的疗效,患有注意力缺陷障碍和胎儿酒精谱系障碍。自2005年以来,他的研究小组和学员在滥用药物领域发表了42篇研究论文。这些论文的合着者包括五名学生,9位医师博士研究研究员,威斯康星大学麦迪逊分校的医师教师以及来自12个非UW研究小组的科学家。在过去的四年中,他的六名学员获得了K23/K08/K12/K01/R21/R03赠款,一名MD博士学位学生获得了F30授予F30和PhD学生的F31 Grant。如果没有K24提供的薪水和研究支持,那么这项工作的大部分以及他的受训者的成功将是不可能的。 K24更新的拟议工作:K24更新将为Fleming博士提供受保护的时间,以指导医学,儿科和家庭医学部门的七个助理教授,并促进他与最近完成R01的三名学员一起写论文的能力。他还将启动一项前瞻性酒精生物标志物研究,该研究将测试250例肝后移植患者样本中磷脂酰乙醇(Peth)和CDT的预测有效性和可靠性。受试者将从四个移植中心招募。将将生物标志物与患者自我报告,家庭成员访谈和移植人员关注以及医疗记录数据进行比较。 Peth和CDT将以六个月的间隔测量一年。意义:K24对于弗莱明博士持续指导新研究人员进行酒精研究和他对酒精生物标志物的研究至关重要。
公共卫生相关性:该研究的目的是找出实验室测试是否可以分辨出肝移植后哪些患者在喝酒。一项积极的研究将有助于医生在损害新肝脏之前识别和治疗患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL F. FLEMING其他文献
MICHAEL F. FLEMING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL F. FLEMING', 18)}}的其他基金
Post-Graduate Research Training Aligned with the NIMH Strategic Plan
符合 NIMH 战略计划的研究生研究培训
- 批准号:
10559585 - 财政年份:2019
- 资助金额:
$ 17.57万 - 项目类别:
Post-Graduate Research Training Aligned with the NIMH Strategic Plan
符合 NIMH 战略计划的研究生研究培训
- 批准号:
10348152 - 财政年份:2019
- 资助金额:
$ 17.57万 - 项目类别:
Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay
乌拉圭新生儿磷脂酰乙醇筛查以检测胎儿酒精暴露情况
- 批准号:
9116730 - 财政年份:2015
- 资助金额:
$ 17.57万 - 项目类别:
Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay
乌拉圭新生儿磷脂酰乙醇筛查以检测胎儿酒精暴露情况
- 批准号:
8886475 - 财政年份:2015
- 资助金额:
$ 17.57万 - 项目类别:
Alcohol Biomarkers In Post Liver Transplant Patients
肝移植后患者的酒精生物标志物
- 批准号:
8321084 - 财政年份:2005
- 资助金额:
$ 17.57万 - 项目类别:
Alcohol Biomarkers in General Clinical Settings
一般临床环境中的酒精生物标志物
- 批准号:
7278651 - 财政年份:2005
- 资助金额:
$ 17.57万 - 项目类别:
Alcohol Biomarkers in General Clinical Settings
一般临床环境中的酒精生物标志物
- 批准号:
7481100 - 财政年份:2005
- 资助金额:
$ 17.57万 - 项目类别:
Alcohol Biomarkers In Post Liver Transplant Patients
肝移植后患者的酒精生物标志物
- 批准号:
7989366 - 财政年份:2005
- 资助金额:
$ 17.57万 - 项目类别:
Alcohol Biomarkers in General Clinical Settings
一般临床环境中的酒精生物标志物
- 批准号:
7124756 - 财政年份:2005
- 资助金额:
$ 17.57万 - 项目类别:
Alcohol Biomarkers in General Clinical Settings
一般临床环境中的酒精生物标志物
- 批准号:
7682257 - 财政年份:2005
- 资助金额:
$ 17.57万 - 项目类别:
相似国自然基金
饮酒刺激肝细胞分泌外泌体对股骨头内H型血管的影响及分子机制
- 批准号:82272508
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
不同饮酒模式下CD11b+Ly6Chigh细胞群的分化及其对酒精性肝损伤的调控机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
不同饮酒模式下CD11b+Ly6Chigh细胞群的分化及其对酒精性肝损伤的调控机制研究
- 批准号:82200656
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
定量设定法定最低饮酒年龄的方法研究
- 批准号:82103950
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
伏隔核多巴胺信号通过调节D1R-、D2R-MSNs活动影响个体差异饮酒行为的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Phosphodiesterase 4B Inhibition as a Therapeutic Target for Alcohol-associated Liver Disease
磷酸二酯酶 4B 抑制作为酒精相关性肝病的治疗靶点
- 批准号:
10354185 - 财政年份:2023
- 资助金额:
$ 17.57万 - 项目类别:
Role of Lysosome Damage in ALD Pathogenesis
溶酶体损伤在 ALD 发病机制中的作用
- 批准号:
10668006 - 财政年份:2023
- 资助金额:
$ 17.57万 - 项目类别:
BEASTS-Novel Biomimetic Liver Platform for Enabling ALD Researchers
BEASTS-为 ALD 研究人员提供支持的新型仿生肝脏平台
- 批准号:
10697452 - 财政年份:2023
- 资助金额:
$ 17.57万 - 项目类别:
Integrating Treatments for Alcohol Use Disorder into Hepatology Clinics
将酒精使用障碍的治疗纳入肝病诊所
- 批准号:
10785211 - 财政年份:2023
- 资助金额:
$ 17.57万 - 项目类别:
1/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease
1/4-综合研究:评估综合护理以改善酒精相关性肝病早期肝移植的生物心理社会结果
- 批准号:
10712618 - 财政年份:2023
- 资助金额:
$ 17.57万 - 项目类别: